Esketamine in Treatment-Resistant Depression: Clinical and Translational Perspectives.
Curr Neuropharmacol July 22, 2026 DOI: 10.2174/011570159x465328260703100233 (opens in new tab)
Study at a glance
AI-extracted from the abstract| Characteristics | Review Peer reviewed |
|---|---|
| Topics | Depression Esketamine |
| Key findings | Reviews evidence that intranasal esketamine provides rapid antidepressant effects in treatment-resistant depression, with a need for supervised administration due to safety concerns, and discusses translational insights into its mechanisms of action. |
Abstract
Esketamine in Treatment-Resistant Depression: Clinical and Translational Perspectives.
Comparable studies
Other narrative reviews on esketamine for depression, most cited first.
| Study | Year | Design | Participants |
|---|---|---|---|
| Synthesizing the Evidence for Ketamine and Esketamine in Treatment-Resistant Depression: An International Expert Opinion on the Available Evidence and Implementation Adults with treatment-resistant depression | 2021 | Review | |
| Long-term safety of ketamine and esketamine in treatment of depression | 2022 | Review | |
| Ketamine, Esketamine, and Arketamine: Their Mechanisms of Action and Applications in the Treatment of Depression and Alleviation of Depressive Symptoms. | 2024 | Review | |
| Variations in BDNF and Their Role in the Neurotrophic Antidepressant Mechanisms of Ketamine and Esketamine: A Review. Patients with depression | 2024 | Narrative review | |
| The Possible Application of Ketamine in the Treatment of Depression in Alzheimer’s Disease | 2022 | Review |